Adjuvant Therapy With Letrozole in Induction of Ovulation With Polycystic Ovarian Syndrome

Polycystic Ovary Clinical Trial

Official title: Sodium-Glucose Co-Transporter-2 Inhibitors as Adjuvant Therapy With Letrozole in Induction of Ovulation in Women With Polycystic Ovarian Syndrome

Status Not yet recruiting

Clinical Trial Summary

The aim of the study is to assess the efficacy of adjuvant therapy dapagliflozin, metformin as monotherapy and combination of both in comparison to control group in induction of ovulation with letrozole in women PCOS, focusing specifically on rates of ovulation and pregnancy.

Clinical Trial Description

The study will be a randomized controlled clinical trial. Once the eligibility from screening visit is determined prior to baseline visit, randomization will be made by computer randomization for women who are admitted to Beni-Suef University Hospital.

• Before initiation of the study, the population will be divided randomly into 4 equal groups: group A, B, C and D. The adjuvant therapy of each group will be group (A) Metformin 1000mg, group (B) Dapagliflozin 10mg, Group(C) Combined Dapagliflozin-Metformin 10/1000mg and group (D) with no adjuvant therapy (control group).

• The adjuvant therapy will be taken once daily with a main meal and started one month before initiation of letrozole. All groups will take letrozole 2.5mg twice daily from the third day of the cycle for 5 days.

This treatment regimen will continue for three cycles unless positive pregnancy is achieved. No diet restriction will be recommended during the study or change in the lifestyle. The population will be asked to inform about any side effects that may happen during the study. A written informed consent will be obtained from each woman participating in the study. ;

Related Conditions & MeSH terms

• Polycystic Ovary
• Polycystic Ovary Syndrome

• NCT number: NCT06405178
• Study type: Interventional
• Source: Beni-Suef University
• Contact: Sara S Sara Salem, MD
• Phone: +201272842226
• Email: sara_abdallah100@yahoo.com
• Status: Not yet recruiting
• Phase: Phase 3
• Start date: September 30, 2024
• Completion date: December 30, 2024